Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases

J. Sany, J. M. Anaya, V. Lussiez, M. Couret, B. Combe, J. P. Daures

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 ± 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 ± 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.

Original languageEnglish (US)
Pages (from-to)1323-1327
Number of pages5
JournalJournal of Rheumatology
Volume18
Issue number9
StatePublished - 1991
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases'. Together they form a unique fingerprint.

Cite this